Understand the Role of Radicava in Amyotrophic Lateral Sclerosis (ALS)

Radicava (ra-dih-CAH-vah, edaravone) is the first treatment approved for amyotrophic lateral sclerosis (ALS) in almost 20 years.

Until now, we've only had riluzole (Rilutek) for this progressive, degenerative nerve disease...also known as Lou Gehrig's disease.

Radicava is a free-radical scavenger...and oxidative stress is one way that cell damage and cell death may occur in ALS.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote